1079. Nevirapine once daily after switch from GPOvir
Session: Poster Abstract Session: HIV: Switching Antiretrovirals
Friday, October 9, 2015
Room: Poster Hall
  • NVP OD.png (294.3 kB)
  • Background: Once-daily combined anti-retroviral therapy (ART) is a preferred regimen of HIV treatment. Nevirapine is a frequently-used non-nucleoside reverse transcriptase inhibitor in Thailand. However, the recommended dose of nevirapine is twice a day and extended-release nevirapine formulation is not available in Thailand. Using once-daily nevirapine could be as effective as twice-daily and may improve patient compliance to ART.

    Methods: We performed observational cohort study of HIV patients treated with stavudine, lamivudine and nevirapine (GPOvir) twice a day. After suppression of HIV, the ART regimen switched to tenofovir, lamivudine and nevirapine (TDF/3TC/NVP) once a day. HIV viral load was performed after switching 3 to 6 months and then every 6 to 12 months. 

    Results: One hundred and fifty six patients (156) were followed in this cohort. Fifty percent were male. Median age was 33 years old (range 23-55). Median follow-up after switching was 25 months (range 6-52). One (0.64%) of the patients developed virological failure during the period of follow-up. Median CD4-T cell was 478 cells per microliters (range 111-1099). Patients reported 100% satisfactory to once-daily nevirapine regimen. 

    Conclusion: Once-daily nevirapine-based ART regimen is effective in suppression of HIV in this cohort study. It improved patient compliance and satisfaction. More systemic randomized controlled trials are needed in order to recommend this regimen widely. 

    Ekkachai Thiansukhon, MD, Medicine, Udon Thani hospital, Udon Thani, Thailand


    E. Thiansukhon, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.